EP0155096B1 - 4-Aza-5 alpha androsténones substitués en 17 bêta et leur utilisation comme inhibiteurs de 5 alpha réductase - Google Patents
4-Aza-5 alpha androsténones substitués en 17 bêta et leur utilisation comme inhibiteurs de 5 alpha réductase Download PDFInfo
- Publication number
- EP0155096B1 EP0155096B1 EP85301122A EP85301122A EP0155096B1 EP 0155096 B1 EP0155096 B1 EP 0155096B1 EP 85301122 A EP85301122 A EP 85301122A EP 85301122 A EP85301122 A EP 85301122A EP 0155096 B1 EP0155096 B1 EP 0155096B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- aza
- androst
- hydrogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 0 CC(CC1)(C(CC2NC)C(C(*)C[C@]3(*)*4N)C1C3(C)N=CC4=O)C2N=O Chemical compound CC(CC1)(C(CC2NC)C(C(*)C[C@]3(*)*4N)C1C3(C)N=CC4=O)C2N=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/38—Unsaturated compounds containing keto groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes
Definitions
- the present invention is concerned with 17p-substituted-4-aza-5a-androstenones, their preparation, and their use as testosterone-5a-reductase inhibitors.
- Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethylisobutyranilide [See Neri et al., Endo., Vol. 91, No. 1 (1972)].
- these products though devoid of hormonal effects, are peripherally active, competing with the natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male foetus of a female host.
- a number of 4-aza steroid compounds are known. See, for example, U.S. Patent Specifications Nos. US-A-2,227,876, 3,239,417, 3,264,301 and 3,285,918; French Patent Specification No. FR-A-1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62,4, pp. 638-640 (1973); Doorenbos and Brown, J. Pharm. Sci., 60, 8, pp. 1234-1235 (1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974).
- EP-A-0 004 949 discloses inter alia that androstenone compounds of the formula: wherein R is hydrogen, methyl or ethyl; R' is hydrogen or methyl; R" is hydrogen or ⁇ -methyl; and Z is ⁇ NHCO ⁇ (C 1-12 alkyl) or ⁇ CO ⁇ NR 9 R 10 , in which each of R 9 and R 10 , independently of the other, is hydrogen, C 1 - 4 straight or branched alkyl or C 3 - 6 cycloalkyl; are active as testosterone 5a-reductase inhibitors.
- the present invention provides novel 17 ⁇ -N-(monosubstituted carbamoyl)-4-aza-5a-androsten-1-en-3- one compounds of the formula: in which R is hydrogen, methyl or ethyl;
- Preferred compounds have the formula: in which R is hydrogen, methyl or ethyl, and R 3 is tertiary alkyl of from 4-8 carbons and having a tertiary carbon atom directly bonded to the carbamoyl nitrogen atom.
- novel compounds of the present invention are prepared from the known steroid ester of the formula: viz., 17 ⁇ -(methoxycarbonyl)-4-aza-5a-androstan-3-one, or another 17 ⁇ -alkoxycarbonyl-4-aza-5 ⁇ -androstan-3-one compound, which may have the indicated substitution indicated by R', R" and R"', by (A) dehydrogenating the starting material to produce the corresponding compound containing a double-bond in the 1,2-position of the A-ring (B), converting the 17-substituent into an N-monosubstituted carbamoyl substituent, and optionally (C) alkylating the A-ring nitrogen to introduce a 4-methyl or 4-ethyl substituent in the A ring.
- Stage (A) dehydrogenation of the 1,2-position of the steroid A ring be carried out using a 4-aza-5a-androstane-3-one-compound having no substituent other than hydrogen attached to the A-ring nitrogen.
- Stage (B) may consist of one or more chemical steps and if desired may take place before stage (A) or following stage (A) or stage (C).
- the product I are formed by (1) heating a 17 ⁇ -alkoxycarbonyl-4-aza-5a-androstan-3-one compound III with a dehydrogenating agent such as benzeneseleninic anhydride in refluxing chlorobenzene to form a 17 ⁇ -alkoxycarbonyl-4-aza-5a-androst-1-en-3-one IV, (2) reacting the latter with sodium hydride under anhydrous conditions in a neutral solvent such as dimethylformamide, (3) contacting the resulting reaction mixture with an alkyl (e.g.
- This ester is treated with an amine of formula R 2- NH 2 , where R is as defined above, to form a 17 ⁇ -(N-R 2 -carbamoyl)-4-aza-5a-androstone-3-one (XI), which is dehydrogenated as previously described to product compound XIV, 17 ⁇ -(N-R 2 -carbamoyl)-4-aza-androst-1-en-3-one.
- the 17 ⁇ -(N-R 2 -carbamoyl) substituent is introduced into a 1713-carboxy androstane compound of formula VI, XII or IX, by treating it in a manner similar to the procedure described in Steroids, Vol. 35, (3), March 1980, p. 1-7 with dicyclohexylcarbodiimide and 1-hydroxybenzotriazole to form the 17 ⁇ -(1-benzotriazoloxycarbonyl)-4-aza-5 ⁇ -androst-1-en-3-one or 17 ⁇ -(1-benzotriazoloxycarbonyl)-4-aza-5 ⁇ -androstan-3-one.
- the 16-methyl derivatives i.e. compounds in which R"' is methyl
- 16-methyl-17-acyl-4-methyl-4-aza-5a-androstan-3-ones e.g. 4,16 ⁇ -dimethyl-17 ⁇ -acetyl-4-aza-5 ⁇ -androstan-3- one, by known dehydrogenation procedures for 4-methyl-4-aza compounds to produce the corresponding 4,16 ⁇ -dimethyl-17(3-acetyl-4-aza-5 ⁇ -androst-1-en-3-one.
- Compounds of the present invention which may be prepared in accordance with the method described above, have been found to be potent antiandrogens by virtue of their ability to specifically inhibit testosterone-5a-reductase and are therefore suitable for treating the hyperandrogenic conditions of acne vulgaris, seborrhea and female hirsutism by topical administration, and for treating all of the above conditions, as well as benign prostatic hypertrophy, by oral parenteral administration.
- the present invention thus also provides oral topical and parenteral pharmaceutical formulations for use in administering the active compounds of the present invention.
- compositions containing the compounds of the present invention as the active ingredient for use in the treatment of benign prostatic hypertrophy can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for systemic administration, as, for example, by oral administration in the form of tablets, capsules, solutions or suspensions, or by intravenous injection.
- the daily dosage of the products may be varied over a wide range varying from 50 to 2,000 mg.
- the compositions are preferably provided in the form of scored tablets containing 5, 10, 25, 50, 100, 150, 250 and 500 mg. of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- An effective amount of the drug is ordinarily supplied at a dosage level of from 1 to 50 mg/kg of body weight per day.
- Capsules containing an active compound of this invention can be prepared by mixing it with lactose and magnesium stearate, calcium stearate, starch, talc, or other carriers, and placing the mixture in gelatin capsules. Tablets may be prepared by mixing the active ingredient with conventional tableting ingredients such as calcium phosphate, lactose, corn starch or magnesium stearate.
- the liquid forms are prepared suitably flavoured suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia and methyl cellulose. Other suitable dispersing agents include glycerin.
- Isotonic preparations which usually contain suitable preservative, are prepared for intravenous administration.
- the compounds of the present invention are administered in the form of pharmaceutical compositions comprising the active compound in combination with a pharmacologically acceptable topically administrable carrier.
- topical pharmaceutical compositions may be in the form of a cream, ointment, gel or aerosol formulation suitable for application to the skin. They ordinarily include 0.1% to 15%, preferably about 5%, of the active compound, based on the total composition.
- a suspension of 25 g of the product of Example 2 in 125 ml of methanol was treated with a solution of KOH (12.5 g) in 12.5 ml of water. After refluxing for 4 hours, the solution was acidified with 6N HCI and then was diluted with water. The crude acid (23.32 g) was separated and dried. It had m.p. 300°C.
- a suspension of 64.7 g of the dioic acid or Step A in 350 ml of ethylene glycol was treated with 80 ml of liquid ammonia.
- the resulting solution was heated at a rate of 3°/min. up to 180°C and was held at that temperature for 15 minutes.
- 1 litre of water was added and the mixture was acidified with 10% hydrochloric acid to a pH of 1.5.
- the product was removed and washed with water, then air dried to leave 57.5 g of the product, m.p. 310°C.
- This material was also obtained by saponification of methyl 3-oxo-4-aza-5 ⁇ -androstane-17 ⁇ -carboxylate (methyl 3-oxo-4-aza-5a-etiocholan-20-oate) in 7% methanolic potassium hydroxide followed by an acidic work-up.
- Example 4D is repeated using t-butylamine in place of 2,2,4-trimethyl-2-pentylamine to obtain N-t-butyl-3-oxo-4-aza-5a-androstane-170-carboxamide, m.p. 274 ⁇ 276°C.
- the product obtained is 23-methyl-4-aza-21-nor-5a-chol-1-ene-3,20-dione, m.p. 283-296°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT85301122T ATE46912T1 (de) | 1984-02-27 | 1985-02-20 | 17 beta-substituierte-4-aza-5-alpha-androstenone und ihre anwendung als 5-alpha-reduktaseinhibitoren. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58406284A | 1984-02-27 | 1984-02-27 | |
US58406184A | 1984-02-27 | 1984-02-27 | |
US584061 | 1984-02-27 | ||
US584062 | 1984-02-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88119105A Division-Into EP0314199B1 (fr) | 1984-02-27 | 1985-02-20 | 4-Aza-5-alpha-androsténones substituées en position 17 bêta et leur utilisation comme inhibiteurs de 5-alpha-réductase |
EP88119105.0 Division-Into | 1985-02-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0155096A2 EP0155096A2 (fr) | 1985-09-18 |
EP0155096A3 EP0155096A3 (en) | 1986-07-02 |
EP0155096B1 true EP0155096B1 (fr) | 1989-10-04 |
Family
ID=27078980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85301122A Expired EP0155096B1 (fr) | 1984-02-27 | 1985-02-20 | 4-Aza-5 alpha androsténones substitués en 17 bêta et leur utilisation comme inhibiteurs de 5 alpha réductase |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0155096B1 (fr) |
JP (1) | JPH0193600A (fr) |
KR (1) | KR900001206B1 (fr) |
AU (4) | AU584321B2 (fr) |
CA (1) | CA1314541C (fr) |
CY (1) | CY1553A (fr) |
DE (2) | DE3584172D1 (fr) |
DK (1) | DK166704B1 (fr) |
ES (1) | ES8702430A1 (fr) |
GR (1) | GR850483B (fr) |
HK (1) | HK63090A (fr) |
IE (2) | IE922862L (fr) |
IL (1) | IL74365A (fr) |
NL (1) | NL930005I2 (fr) |
NZ (1) | NZ211145A (fr) |
PT (1) | PT80010B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0823436A2 (fr) | 1992-11-19 | 1998-02-11 | MERCK & CO. INC. | Formes I et II polymorphiques de finastéride |
CN104292293A (zh) * | 2014-09-17 | 2015-01-21 | 广东众生药业股份有限公司 | 一种度他雄胺杂质i的制备方法 |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120742A (en) * | 1984-02-27 | 1992-06-09 | Merck & Co., Inc. | 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors |
US5138063A (en) * | 1984-02-27 | 1992-08-11 | Merck & Co., Inc. | 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones |
US5151429A (en) * | 1984-02-27 | 1992-09-29 | Merck & Co., Inc. | 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors |
US5571817A (en) * | 1984-02-27 | 1996-11-05 | Merck & Co., Inc. | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
US5049562A (en) * | 1984-02-27 | 1991-09-17 | Merck & Co., Inc. | 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors |
JPS62201896A (ja) * | 1986-02-28 | 1987-09-05 | Shiseido Co Ltd | 多毛症治療剤 |
US4845104A (en) * | 1986-11-20 | 1989-07-04 | Merck & Co., Inc. | Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones |
EP0271219B1 (fr) * | 1986-11-20 | 1992-07-29 | Merck & Co. Inc. | Composition pharmaceutique topique contenant 17-bêta-methoxycarbonyl-4-methyl-4 -aza-5-alpha-androst-1-en-3-one |
US4888336A (en) * | 1987-01-28 | 1989-12-19 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
DE3888378T2 (de) * | 1987-04-03 | 1994-09-29 | Merck & Co Inc | Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen. |
DE3888994T2 (de) * | 1987-04-03 | 1994-11-03 | Merck & Co Inc | Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen. |
NZ225100A (en) * | 1987-06-29 | 1991-09-25 | Merck & Co Inc | Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates |
US5116983A (en) * | 1988-04-18 | 1992-05-26 | Merck & Co., Inc. | Dehydrogenation process intermediates |
US5084574A (en) * | 1988-04-18 | 1992-01-28 | Merck & Co., Inc. | Dehydrogenation process |
US5237061A (en) * | 1988-10-31 | 1993-08-17 | Merck & Co., Inc. | Methods of synthesizing benign prostatic hypertropic agents and their intermediates |
CA2023157A1 (fr) * | 1989-08-21 | 1991-02-22 | Gary H. Rasmusson | 17 beta-acyl-4-aza-5-alpha-androst-1-ene-3-ones utilsiables comme inhibiteurs de l'alpha-reductase |
US5021575A (en) * | 1989-11-13 | 1991-06-04 | Merck & Co., Inc. | Method for introducing a 1,2 double bond into azasteroids |
GB9002922D0 (en) * | 1990-02-09 | 1990-04-04 | Erba Carlo Spa | 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation |
EP0462664A3 (en) * | 1990-06-20 | 1992-11-25 | Merck & Co. Inc. | Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents |
EP0462662A3 (en) * | 1990-06-20 | 1992-08-19 | Merck & Co. Inc. | 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones |
EP0462665A3 (en) * | 1990-06-20 | 1993-06-30 | Merck & Co. Inc. | Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors |
US5162332A (en) * | 1990-06-20 | 1992-11-10 | Merck & Co., Inc. | Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors |
US5151430A (en) * | 1990-06-20 | 1992-09-29 | Merck & Co., Inc. | Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents |
US5061802A (en) * | 1990-06-20 | 1991-10-29 | Merck & Co. Inc. | 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents |
US5098908A (en) * | 1990-06-20 | 1992-03-24 | Merck & Co., Inc. | 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors |
US5091380A (en) * | 1990-06-28 | 1992-02-25 | Merck & Co., Inc. | N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors |
US5120847A (en) * | 1990-08-27 | 1992-06-09 | Merck & Co., Inc. | Process for iodinating or brominating the α-methylenic carbon of a secondary amide |
US5091534A (en) * | 1990-08-27 | 1992-02-25 | Merck & Co., Inc. | Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids |
US5061803A (en) * | 1990-09-24 | 1991-10-29 | Merck & Co., Inc. | Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes |
US5061801A (en) * | 1990-09-24 | 1991-10-29 | Merck & Co., Inc. | Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones |
CA2050824A1 (fr) * | 1990-09-24 | 1992-03-25 | John M. Williams | Methode de preparation de 3-oxo-4-azaandrost-1-en-17.beta.-ones |
IE76452B1 (en) * | 1990-10-29 | 1997-10-22 | Sankyo Co | Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use |
NZ241979A (en) * | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
GB9115676D0 (en) * | 1991-07-19 | 1991-09-04 | Erba Carlo Spa | Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives |
US5304562A (en) * | 1991-10-09 | 1994-04-19 | Ciba-Geigy Corporation | 17β-substituted Aza-androstane derivatives |
EP0547687A1 (fr) * | 1991-12-18 | 1993-06-23 | Merck & Co. Inc. | 17-bêta-substitués adamantyle/norbornanyle-4-aza-5-alpha-androsta-1-en-3-ones et androsta-3-ones |
ES2118222T3 (es) * | 1991-12-20 | 1998-09-16 | Glaxo Wellcome Inc | Inhibidores de 5-alfa-testosterona reductasa. |
US5698720A (en) * | 1992-04-20 | 1997-12-16 | Sankyo Company, Limited | Steroid derivatives |
DE69311837T2 (de) * | 1992-04-20 | 1998-02-12 | Sankyo Co | Steroide zur Behandlung von Prostatisch-Hypertrophe, ihre Herstellung und Verwendung |
CA2135173A1 (fr) * | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Derives de 4-azasteroides |
CZ283894A3 (en) * | 1992-05-20 | 1995-09-13 | Merck & Co Inc | 7beta-substituted 4-aza-5alpha-cholestanones, their use for the preparation of pharmaceutical preparations and pharmaceutical compositions containing thereof |
US5237064A (en) * | 1992-05-20 | 1993-08-17 | Merck & Co., Inc. | Process for producing 7β-substituted-aza-5αandrostan-3-ones |
JPH07508034A (ja) * | 1992-05-20 | 1995-09-07 | メルク エンド カンパニー インコーポレーテッド | 17−アミノ置換4−アザステロイド5α−レダクターゼ阻害剤 |
ATE195530T1 (de) * | 1992-05-20 | 2000-09-15 | Merck & Co Inc | 17-ether und thioether von 4-aza-steroiden |
ES2149208T3 (es) * | 1992-05-20 | 2000-11-01 | Merck & Co Inc | Inhibidores 4-azaesteroides de 5-alfa-reductasa. |
AU674145B2 (en) * | 1992-05-20 | 1996-12-12 | Merck & Co., Inc. | New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors |
WO1993023420A1 (fr) * | 1992-05-20 | 1993-11-25 | Merck & Co., Inc. | NOUVEAUX 4-AZA-5α-ANDROSTANE-3-ONES SUBSTITUES EN POSITION 7β EN TANT QU'INHIBITEURS DE LA 5α-REDUCTASE |
AU4251993A (en) * | 1992-05-20 | 1993-12-13 | Merck & Co., Inc. | Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors |
PL175591B1 (pl) * | 1992-05-21 | 1999-01-29 | Endorecherche Inc | Środek farmaceutyczny do hamowania 5alfa-reduktazy testosteronowej |
GB9216284D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives |
GB9216329D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives |
US5302589A (en) * | 1992-08-07 | 1994-04-12 | Glaxo, Inc. | Heterocyclic inhibitors of 5-α-testosterone reductase |
HU212459B (en) * | 1992-10-02 | 1996-06-28 | Richter Gedeon Vegyeszet | Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them |
US5278159A (en) * | 1992-10-06 | 1994-01-11 | Merck & Co., Inc. | Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors |
US5359071A (en) * | 1993-03-12 | 1994-10-25 | Merck & Co., Inc. | 15-substituted 4-azasteroids |
WO1994021614A1 (fr) * | 1993-03-24 | 1994-09-29 | Merck & Co., Inc. | DERIVES DE 3-PHENANTHRIDINONES SUBSTITUES, UTILISES COMME INHIBITEURS DE LA 5α-REDUCTASE |
DE69331763T2 (de) * | 1993-06-24 | 2002-10-02 | Richter Gedeon Vegyeszeti Gyar R.T., Budapest | Neues verfahren zum herstellen von 17 beta-substituierten 4-azaandrostan-derivaten |
CA2165077A1 (fr) * | 1993-06-28 | 1995-01-05 | Philippe L. Durette | 4-azapregnanes, inhibiteurs des isozymes de 5.alpha.-reductase |
US5438061A (en) * | 1993-07-16 | 1995-08-01 | Merck & Co., Inc. | 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors |
TW369521B (en) * | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
TW382595B (en) * | 1993-10-15 | 2000-02-21 | Merck & Co Inc | Pharmaceutical composition for use in arresting and reversing androgenic alopecia |
US5547957A (en) * | 1993-10-15 | 1996-08-20 | Merck & Co., Inc. | Method of treating androgenic alopecia with 5-α reductase inhibitors |
WO1995011254A1 (fr) | 1993-10-21 | 1995-04-27 | Merck & Co., Inc. | INHIBITEURS DE L'ISOZYME 5α-REDUCTASE 1 DE 4-AZA-ANDROSTANE-5 A SUBSTITUTION EN POSITION 16 |
GB9415178D0 (en) * | 1994-07-28 | 1994-09-21 | Erba Carlo Spa | 4-azasteroids with side-chain fluoroketones |
US5541322A (en) * | 1994-10-14 | 1996-07-30 | Glaxo Wellcome Inc. | Synthesis of 6-azaandrostenones |
US5595996A (en) * | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
US5656613A (en) * | 1995-01-04 | 1997-08-12 | Merck & Co., Inc. | Treatment of hyperandrogenic conditions |
GB0026876D0 (en) * | 2000-11-03 | 2000-12-20 | Glaxo Group Ltd | Process |
WO2003020311A1 (fr) * | 2001-08-28 | 2003-03-13 | Fujisawa Pharmaceutical Co., Ltd. | Remedes contre les maladies de la peau |
ES2287474T3 (es) | 2002-04-24 | 2007-12-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Combinacion farmaceutica para el tratamiento de la hiperplasia prostatica benigna o para la prevencion a la largo plazo de la retencion urinaria aguda. |
HU227117B1 (en) | 2002-05-10 | 2010-07-28 | Richter Gedeon Nyrt | Process for dehydrogenation of aza-androstane compounds |
CN1314241C (zh) * | 2002-09-27 | 2007-05-02 | 华为技术有限公司 | 在城域网相同虚容器映射通道内传送不同用户数据的方法 |
KR100508019B1 (ko) | 2003-07-19 | 2005-08-17 | 한미약품 주식회사 | 고순도 1-안드로스텐 유도체의 제조 방법 |
US7998970B2 (en) | 2004-12-03 | 2011-08-16 | Proteosys Ag | Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders |
EP2050436A1 (fr) | 2007-12-21 | 2009-04-22 | Siegfried Generics International AG | Composition pharmaceutique qui comporte de la dutastéride |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3285918A (en) * | 1962-04-18 | 1966-11-15 | Norman J Doorenbos | 1', 4', 5', 6'-tetrahydropyrimidino[a-4, 3]-4-aza-5-cholestene |
AU527030B2 (en) * | 1978-04-13 | 1983-02-10 | Merck & Co., Inc. | 4-aza-17-substituted-5a-androstan-3-ones |
US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
KR830000085B1 (ko) * | 1978-04-13 | 1983-02-08 | 제임스 에프. 너우톤 | 5α-환원효소 억제제로서 유용한 4-아자-17-치환-5α-안드로스탄-3-온류의 제조방법 |
US4220775A (en) * | 1979-03-15 | 1980-09-02 | Merck & Co., Inc. | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors |
GB8505862D0 (en) * | 1985-03-07 | 1985-04-11 | Erba Farmitalia | Steroidic 5alpha-reductase inhibitors |
-
1985
- 1985-02-18 NZ NZ211145A patent/NZ211145A/xx unknown
- 1985-02-18 IL IL74365A patent/IL74365A/xx not_active IP Right Cessation
- 1985-02-20 DE DE8888119105T patent/DE3584172D1/de not_active Expired - Fee Related
- 1985-02-20 EP EP85301122A patent/EP0155096B1/fr not_active Expired
- 1985-02-20 DE DE8585301122T patent/DE3573429D1/de not_active Expired
- 1985-02-26 CA CA000475184A patent/CA1314541C/fr not_active Expired - Lifetime
- 1985-02-26 ES ES540705A patent/ES8702430A1/es not_active Expired
- 1985-02-26 PT PT80010A patent/PT80010B/pt unknown
- 1985-02-26 AU AU39167/85A patent/AU584321B2/en not_active Expired
- 1985-02-26 DK DK085985A patent/DK166704B1/da not_active IP Right Cessation
- 1985-02-26 GR GR850483A patent/GR850483B/el not_active IP Right Cessation
- 1985-02-26 IE IE922862A patent/IE922862L/xx unknown
- 1985-02-26 IE IE47685A patent/IE58058B1/en not_active IP Right Cessation
- 1985-02-26 KR KR1019850001200A patent/KR900001206B1/ko not_active IP Right Cessation
-
1988
- 1988-06-01 JP JP63135348A patent/JPH0193600A/ja active Granted
-
1989
- 1989-04-18 AU AU33135/89A patent/AU626293B2/en not_active Expired
-
1990
- 1990-08-09 HK HK630/90A patent/HK63090A/xx not_active IP Right Cessation
-
1991
- 1991-02-06 AU AU70835/91A patent/AU7083591A/en not_active Abandoned
- 1991-03-22 CY CY1553A patent/CY1553A/xx unknown
-
1992
- 1992-10-30 AU AU27481/92A patent/AU651741B2/en not_active Ceased
-
1993
- 1993-02-09 NL NL930005C patent/NL930005I2/nl unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0823436A2 (fr) | 1992-11-19 | 1998-02-11 | MERCK & CO. INC. | Formes I et II polymorphiques de finastéride |
CN104292293A (zh) * | 2014-09-17 | 2015-01-21 | 广东众生药业股份有限公司 | 一种度他雄胺杂质i的制备方法 |
CN104292293B (zh) * | 2014-09-17 | 2016-04-06 | 广东众生药业股份有限公司 | 一种度他雄胺杂质i的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
NZ211145A (en) | 1988-10-28 |
AU7083591A (en) | 1991-07-11 |
AU3313589A (en) | 1989-08-10 |
DK166704B1 (da) | 1993-06-28 |
DK85985D0 (da) | 1985-02-26 |
AU651741B2 (en) | 1994-07-28 |
IE922862L (en) | 1985-08-27 |
JPH0193600A (ja) | 1989-04-12 |
AU3916785A (en) | 1985-09-05 |
KR850006185A (ko) | 1985-10-02 |
EP0155096A2 (fr) | 1985-09-18 |
DE3584172D1 (de) | 1991-10-24 |
EP0155096A3 (en) | 1986-07-02 |
AU626293B2 (en) | 1992-07-30 |
PT80010A (en) | 1985-03-01 |
NL930005I2 (nl) | 1993-09-16 |
HK63090A (en) | 1990-08-17 |
DE3573429D1 (en) | 1989-11-09 |
IE58058B1 (en) | 1993-06-16 |
IL74365A (en) | 1990-07-26 |
IL74365A0 (en) | 1985-05-31 |
JPH0541638B2 (fr) | 1993-06-24 |
PT80010B (pt) | 1987-09-18 |
KR900001206B1 (ko) | 1990-02-28 |
ES8702430A1 (es) | 1987-01-01 |
AU2748192A (en) | 1993-03-18 |
CY1553A (en) | 1991-03-22 |
NL930005I1 (nl) | 1993-04-01 |
CA1314541C (fr) | 1993-03-16 |
DK85985A (da) | 1985-10-22 |
ES540705A0 (es) | 1987-01-01 |
AU584321B2 (en) | 1989-05-25 |
IE850476L (en) | 1985-08-27 |
GR850483B (fr) | 1985-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0155096B1 (fr) | 4-Aza-5 alpha androsténones substitués en 17 bêta et leur utilisation comme inhibiteurs de 5 alpha réductase | |
US4760071A (en) | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors | |
EP0314199B1 (fr) | 4-Aza-5-alpha-androsténones substituées en position 17 bêta et leur utilisation comme inhibiteurs de 5-alpha-réductase | |
EP0285383B1 (fr) | Traitement des carcinomes prostatiques avec des 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-ones | |
US4859681A (en) | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors | |
US5049562A (en) | 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors | |
EP0271220B1 (fr) | Analogues oxydés des 17-bêta-carbamoyl-N-mono substitué-4-aza-5-alpha-androst-1-en-3-ones | |
EP0285382B1 (fr) | Traitement d'alopécia androgénique avec 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones | |
US5120742A (en) | 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors | |
US5571817A (en) | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] | |
EP0271219A1 (fr) | Composition pharmaceutique topique contenant 17-bêta-methoxycarbonyl-4-methyl-4 -aza-5-alpha-androst-1-en-3-one | |
US5151429A (en) | 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors | |
EP0414490A2 (fr) | 17-Bêta-acyl-4-aza-5-alpha-androst-1-ene-3one comme inhibiteurs de 5-alpha réductase | |
US5061802A (en) | 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents | |
EP0462662A2 (fr) | 17-Bêta-N-monosubstitués par adamantane/norborane carbamoyl-4-aza-5-alpha-androst-1-en-3-ones et androstan-3-ones | |
US5138063A (en) | 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones | |
EP0547691B1 (fr) | Utilisation de 17B-N-mono-substitué-carbamoyl-4-aza-5D-androst-1-en-3-ones pour la préparation de médicaments pour la prévention de carcinomes de la prostate | |
EP0462664A2 (fr) | 17-Bêta-thiobenzoyle-4-aza-5-alpha-androst-1-en-3-ones comme agents antiandrogéniques | |
US5162332A (en) | Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors | |
US5151430A (en) | Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents | |
EP0462665A2 (fr) | 17-Bêta-polyaroyle-4-aza-5-alpha-androst-1-en-3-ones comme inhibiteurs des réductases des steroides | |
IE60007B1 (en) | 17beta-substituted -4-aza-5alpha-androstenones and their use as 5alpha-reductase inhibitors | |
EP0547690A1 (fr) | Utilisation de 17B-acyl-4-aza-5d-androst-1-en-3-ones pour la préparation d'un médicament pour la prévention de carcinomes de la prostate | |
BG61203B2 (bg) | 17 бета-n-моносубституирани карбамоил-4-аза-5-андрост- 1-ен-3-они действуващи като инхибитори на тестостерон 5 алфа-редуктазата |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
ITCL | It: translation for ep claims filed |
Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19861115 |
|
17Q | First examination report despatched |
Effective date: 19871016 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 46912 Country of ref document: AT Date of ref document: 19891015 Kind code of ref document: T |
|
XX | Miscellaneous (additional remarks) |
Free format text: TEILANMELDUNG 88119105.0 EINGEREICHT AM 20/02/85. |
|
REF | Corresponds to: |
Ref document number: 3573429 Country of ref document: DE Date of ref document: 19891109 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 85301122 Country of ref document: AT Kind code of ref document: T |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
MEDA | It: supplementary protection certificate for pharmaceutical products: examined |
Free format text: CCP 395, 19920630; MERCK & CO.,INC. |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CC Free format text: FRCC 92C0477, 920623 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CB Free format text: FRCB 92C0477, 850220 |
|
MEDD | It: supplementary protection certificate for pharmaceutical products: granted |
Free format text: CCP 403, 19920701; MERCK & CO., INC. |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: GBCTFFSPC/GB93/006, 930108 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: AC1 Free format text: NLAC1 930005, 930209 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CL |
|
CCPA | Be: application for a complementary protection certificate |
Free format text: 093C0055 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: GBCTFGSPC/GB93/006, 930603, EXPIRES:20070526 |
|
MEDF | It: supplementary protection certificate for pharmaceutical products: office refusal |
Free format text: CCP 458, 19930701; MERCK & CO., INC. |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: KC1 Free format text: NLKC1 930005, 20050220, EXPIRES:20070526 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CR Free format text: FRCR 93C0057, 930702 |
|
EPTA | Lu: last paid annual fee | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCF Free format text: 85301122 |
|
CCPV | Be: grant of a complementary protection certificate |
Free format text: 093C0055, EXPIRES 20070527 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: CCP Free format text: LUCCP 88316, EXPIRES:20070527 |
|
EAL | Se: european patent in force in sweden |
Ref document number: 85301122.9 |
|
ITTA | It: last paid annual fee | ||
REG | Reference to a national code |
Ref country code: AT Ref legal event code: ESZA Ref document number: 85301122 Country of ref document: AT Kind code of ref document: T Free format text: PRODUCT NAME: FINASTERIDE Spc suppl protection certif: SZ 93/1994 Filing date: 19941219 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCG Free format text: 9490123, 920904, EXPIRES: 20070427 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCF Free format text: PRODUCT NAME: FINASTERID; OICM 51774/19930128 Spc suppl protection certif: C00155096/01 Filing date: 19951212 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCG Free format text: PRODUCT NAME: FINASTERID; OICM 51774/19930128 Spc suppl protection certif: C00155096/01 Filing date: 19951212 Extension date: 20080127 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CX Free format text: FRCX 93C0057, 930702 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCG Free format text: 9490123, 920904, EXPIRES: 20070903 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: EEZF Ref document number: 85301122 Country of ref document: AT Kind code of ref document: T Free format text: PRODUCT NAME: FINASTERIDE Spc suppl protection certif: SZ 93/1994 Filing date: 19941219 Extension date: 20070428 Effective date: 20000215 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20040107 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20040108 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20040112 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20040121 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20040202 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20040203 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040227 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20040322 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20040518 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050219 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050219 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050220 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050220 |
|
BE20 | Be: patent expired |
Owner name: *MERCK & CO. INC. Effective date: 20050220 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Ref country code: GB Ref legal event code: CTFE Free format text: SPC/GB93/006: 20050220, EXPIRES: 20070526 Spc suppl protection certif: SPC/GB93/006 Filing date: 20050220 Expiry date: 20070526 |
|
EUG | Se: european patent has lapsed | ||
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20050220 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: EELA Ref document number: 46912 Country of ref document: AT Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: SPCE Free format text: SPC/GB93/006:, EXPIRES: 20070526 Spc suppl protection certif: SPC/GB93/006 Expiry date: 20070526 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCN Free format text: FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH Spc suppl protection certif: C00155096/01 Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE VSP |
|
BE20 | Be: patent expired |
Owner name: *MERCK & CO. INC. Effective date: 20050220 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: CCRE Free format text: PRODUCT NAME: FINASTERIDUM; NAT. REG..: 922 IS 151 F 3 19930125; FIRST REG.: GB PL 0025/0279 19920527 Spc suppl protection certif: 93C0055 Filing date: 19930610 Expiry date: 20050220 Extension date: 20070527 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCL Spc suppl protection certif: C00155096/01 |